Cellectis publishes article in Frontiers in Immunology and reveals…
NEW YORK, May 12, 2023 (GLOBE NEWSWIRE) – Cellectis (the “Company”) CLLSa clinical-stage biotechnology company using its breakthrough gene-editing platform to develop life-saving cell and